International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 33-36 , July 2010

Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model

  • Suganthini Krishnan-Natesan

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
    • John D. Dingell VA Medical Center, Detroit, MI, USA
    • Corresponding Author InformationCorresponding author. Present address: Department of Medicine, Division of Infectious Diseases, Wayne State University/John D. Dingell VA Medical Center, 4646 John R Street, Room B4326, Detroit, MI 48201, USA. Tel.: +1 313 576 4486; fax: +1 313 577 1858.
    • ,
  • Elias K. Manavathu

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
    • ,
  • Jessica L. Cutright

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
    • ,
  • Pranatharthi H. Chandrasekar

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA

Received 10 June 2009 ,Accepted 13 February 2010.

References 

  1. Glöckner A, Steinbach A, Vehreschild JJ, Cornely OA. Treatment of invasive candidiasis with echinocandins. Mycoses. 2009;52:476–486
  2. Sobel JD, Revankar SG. Echinocandins—first-choice or first-line therapy for invasive candidiasis?. N Engl J Med. 2007;356:2525–2526
  3. Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs. 2006;11:231–235
  4. Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother. 2007;8:1479–1492
  5. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl. 3):56–60
  6. Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363–369
  7. Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez JA, Teppler H, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006;106:466–473
  8. Lichtenstern CT, Nguyen H, Schemmer P, Hoppe-Tichy T, Weigand MA. Efficacy of caspofungin in invasive candidiasis and candidemia—de-escalation strategy. Mycoses. 2008;51(Suppl. 1):35–46
  9. Ellis M, Frampton C, Joseph J, Alizadeh H, Kristensen J, Hauggaard A, et al. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol. 2006;55:1357–1365
  10. Cross SA, Scott LJ. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs. 2008;68:2225–2255
  11. Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009;29:17–30
  12. Nir-Paz R, Moses AA. Anidulafungin and fluconazole for candidiasis. N Engl J Med. 2007;357:1347–1348
  13. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–2482
  14. Onishi J, Meinz M, Thompson J, Curotto J, Dreikorn S, Rosenbach M, et al. Discovery of novel antifungal (1,3)-β-d-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000;44:368–377
  15. Douglas CM, D’Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-d-glucan synthase inhibitors. Antimicrob Agents Chemother. 1997;41:2471–2479
  16. Radding JA, Heidler SA, Turner WW. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Antimicrob Agents Chemother. 1998;42:1187–1194
  17. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–893
  18. Arevalo MP, Carrillo-Munoz AJ, Salgado J, Cardenes D, Brio S, Quindos G, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51:163–166
  19. Dannaoui E, Lortholary O, Raoux D, Bougnoux ME, Galeazzi G, Lawrence C, et al. Comparative in vitro activity of caspofungin and micafungin, using the method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), against yeast isolates from France (2005–2006). Antimicrob Agents Chemother. 2008;52:778–781
  20. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46:2620–2629
  21. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150–156
  22. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ, et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006;44:760–763
  23. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2008;46:2155–2159
  24. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425–5427
  25. Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis. 2007;20:587–591
  26. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:539–550
  27. Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother. 2006;50:3695–3700
  28. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41:2339–2344
  29. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, et al. Disposition of caspofungin, a novel antifungal agent in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother. 2004;48:1272–1280
  30. Stone JA, Holland SD, Wicjersham PJ, Sterrett A, Schwartz M, Bonfiglio C, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002;46:739–745
  31. Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52:2673–2676

PII: S0924-8579(10)00112-3

doi: 10.1016/j.ijantimicag.2010.02.020

International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 33-36 , July 2010

Article Tools

* Image Usage & Resolution